Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Gastro-enteropancreatic neuroendocrine tumor × cabozantinib × 30 days × Clear all

Sponsor

Conditions

Carcinoma, Renal Cell 14 Urinary Bladder Neoplasms 3 Urethral Neoplasms 3 Osteosarcoma 3 Melanoma 3 Clear-cell metastatic renal cell carcinoma 3 Urogenital Neoplasms 2 Ureteral Neoplasms 2 Small Cell Lung Carcinoma 2 Sarcoma, Ewing 2 Prostatic Neoplasms 2 Penile Neoplasms 2 Neuroendocrine Tumors 2 Kidney Neoplasms 2 Carcinoma, Transitional Cell 2 Carcinoma, Hepatocellular 2 Carcinoma 2 Brain Neoplasms 2 Urachal adenocarcinoma 1 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Sarcoma, Kaposi 1 Refractory Differentiated Thyroid Gland Carcinoma 1 Ovarian Neoplasms 1 Oropharyngeal Neoplasms 1 Non functioning pancreatic endocrine tumor 1 Neurofibromatosis 1 1 Neurofibroma, Plexiform 1 Neoplasm Metastasis 1 Mouth Neoplasms 1

Interventions

pasireotide 1 E-7386 1 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡